Guildford, UK, 29 July 2011: ReNeuron announces that its Annual Report and Accounts for the year ended 31 March 2011 and the Notice of the 2011 Annual General Meeting (AGM) have been sent to shareholders and are also available on the Company’s website at

ReNeuron’s AGM will be held at the offices of Covington & Burling LLP, 265 Strand, London, WC2R 1BH on 15 September 2011 at 10.00 am.

Copies of the above documents have also been submitted to the UK Listing Authority for publication through the UK Listing Authority’s Document Viewing Facility, which is situated at The Financial Services Authority, 25 The North Colonnade, Canary Wharf, London, E14 5HS.


Michael Hunt, Chief Executive Officer – ReNeuron                    +44 (0) 1483 302560
Dr John Sinden, Chief Scientific Officer – ReNeuro

Lisa Baderoon, Mark Court, Isabel Podda                                +44 (0) 20 7466 5000
Buchanan Communications                                              

Antony Legge, Oliver Rigby                                                         +44 (0) 20 7776 6550
Daniel Stewart & Company plc (Nomad and Joint Broker)                             

James Gallagher, Steve Waterman                                            +44 (0) 20 3206 7000
Matrix Corporate Capital LLP (Joint Broker)                               


About ReNeuron

ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments.  ReNeuron’s lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development.  The Company is also developing stem cell therapies for other conditions such as peripheral arterial disease, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications – its ReNcell® products for use in academic and commercial research.  The Company’s ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.

ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as “should”, “expects”, “estimates”, “believes” or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron’s current expectations and assumptions as to future events and circumstances that may not prove accurate.  A number of factors could cause ReNeuron’s actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.